Atos Healthcare muscles up for further UK marketisation prospects:
This article was originally published in Clinica
Atos Consulting has strengthened its team of UK healthcare business developers, with the appointment of Sunil Patel. Through the French group's London-based Atos Healthcare division, which has already secured important "marketised" NHS service delivery contracts, he will focus on developing business opportunities with the DoH, the NHS and private healthcare organisations. In a veiled reference to the current NHS marketisation drive, Atos said the appointment "demonstrates our commitment to this important and growing market". Mr Patel joins from Accenture, where, over 17 years, he worked on "high-profile NHS projects".
You may also be interested in...
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.
Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.